Analyzing Tourmaline Bio (NASDAQ:TRML) and Silexion Therapeutics (NASDAQ:SLXN)

Silexion Therapeutics (NASDAQ:SLXN) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership.

Volatility and Risk

Silexion Therapeutics has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Silexion Therapeutics and Tourmaline Bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silexion Therapeutics	0	0	1	0	3.00
Tourmaline Bio	0	0	7	0	3.00

Silexion Therapeutics presently has a consensus price target of $5.00, suggesting a potential upside of 418.30%. Tourmaline Bio has a consensus price target of $49.33, suggesting a potential upside of 217.87%. Given Silexion Therapeutics’ higher probable upside, equities research analysts clearly believe Silexion Therapeutics is more favorable than Tourmaline Bio.

Earnings and Valuation

This table compares Silexion Therapeutics and Tourmaline Bio”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silexion Therapeutics	N/A	N/A	$260,000.00	N/A	N/A
Tourmaline Bio	N/A	N/A	-$42.12 million	($3.21)	-4.83

Institutional and Insider Ownership

10.9% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are held by institutional investors. 33.0% of Silexion Therapeutics shares are held by insiders. Comparatively, 11.0% of Tourmaline Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Silexion Therapeutics and Tourmaline Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silexion Therapeutics	N/A	N/A	-249.43%
Tourmaline Bio	N/A	-20.97%	-20.56%

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

About Tourmaline Bio

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.